Last updated: October 14, 2026
Norcuron is the former brand name for vecuronium bromide, an intermediate-duration nondepolarizing neuromuscular blocking agent used with general anesthesia and mechanical ventilation. Its commercial position is mature and largely generic. U.S. brand revenue is not publicly reported as a separate business line, while current market economics are driven by hospital contracts, generic injectable supply, manufacturing capacity, and shortage risk rather than by patent exclusivity.
What is Norcuron and how is vecuronium bromide used?
Norcuron contains vecuronium bromide, a competitive antagonist of acetylcholine at the neuromuscular junction. It produces skeletal-muscle paralysis but does not provide anesthesia or analgesia. The drug is administered intravenously and is used as an adjunct to general anesthesia for endotracheal intubation and surgical muscle relaxation. It has also been used in mechanically ventilated patients under intensive-care protocols.
The FDA label identifies the principal clinical characteristics as follows:
| Attribute |
Norcuron / vecuronium bromide |
| Active ingredient |
Vecuronium bromide |
| Drug class |
Nondepolarizing neuromuscular blocker |
| Route |
Intravenous |
| Dosage form |
Sterile injection, supplied as a powder requiring reconstitution |
| Primary use |
Adjunct to general anesthesia |
| Main competitors |
Rocuronium, pancuronium, cisatracurium, atracurium, succinylcholine |
| Reversal options |
Neostigmine-based reversal; sugammadex may reverse certain steroidal neuromuscular blockers, including vecuronium |
| Commercial status |
Mature product with generic competition |
| Patent position |
Core product exclusivity has expired |
Vecuronium has a lower cardiovascular-effect profile than some older neuromuscular blockers. Its limitations include the need for neuromuscular monitoring, prolonged paralysis in some patients, and dependence on sterile injectable manufacturing capacity.
What is the FDA regulatory status of Norcuron?
Norcuron was approved in the United States as an injectable vecuronium bromide product. The original branded product was associated with Organon. The U.S. market subsequently shifted to generic vecuronium bromide injections approved through abbreviated new drug applications, or ANDAs.
The FDA’s Drugs@FDA and Orange Book systems distinguish between the original new drug application and later generic approvals. The brand’s commercial status should therefore be separated from the regulatory availability of the active ingredient:
| Regulatory issue |
Current commercial implication |
| Original Norcuron approval |
Historical branded approval |
| Generic ANDAs |
Permit competing vecuronium bromide injection products |
| New chemical entity exclusivity |
Expired |
| Core patent exclusivity |
Expired |
| Orange Book relevance |
Limited mainly to historical listed patents and reference-product information |
| Current FDA pathway |
Generic manufacturers generally rely on ANDA approval |
| Regulatory barrier |
Sterility, potency, stability, packaging, and manufacturing compliance |
A product may remain listed in historical FDA records even after the original brand is no longer commercially prominent. FDA listing status does not establish active sales, current manufacturing, or meaningful brand market share.
When did Norcuron lose exclusivity?
Norcuron lost meaningful U.S. market exclusivity after expiration of the original product’s patent and regulatory protections. Vecuronium is now a mature generic injectable, and the commercial market does not depend on a live composition-of-matter patent.
Public sources do not provide a current standalone Norcuron revenue series or a single, reliable “loss of exclusivity” event that explains today’s market. The commercial transition occurred over time as generic vecuronium products entered hospital formularies and purchasing contracts.
Norcuron exclusivity timeline
| Period |
Market event |
Commercial effect |
| 1980s |
Vecuronium introduced as a branded neuromuscular blocker |
Brand-led pricing and formulary adoption |
| 1990s and 2000s |
Core patent and regulatory exclusivity aged out |
Generic entry became possible |
| Post-exclusivity period |
Generic vecuronium injection gained hospital access |
Price competition increased |
| 2010s |
Market matured as an injectable hospital generic |
Contracting and supply reliability became more important |
| 2020 onward |
COVID-19 increased demand for several injectable sedatives and paralytics |
Temporary demand and supply volatility |
| Current market |
Vecuronium remains a niche hospital generic |
Low differentiation and limited brand pricing power |
What patents protect Norcuron and vecuronium bromide?
The principal Norcuron product is no longer protected by an enforceable U.S. composition-of-matter patent that would prevent generic vecuronium bromide injection. Product-level patents associated with the historical branded product have expired or ceased to provide meaningful commercial exclusivity.
The modern IP position is therefore narrow:
| Patent category |
Relevance to Norcuron |
| Composition of matter |
Expired |
| Basic injectable formulation |
No meaningful current exclusivity identified |
| Method of anesthesia use |
Generally weak as a commercial barrier because the product is established and generic |
| Manufacturing process |
Potentially relevant to a specific supplier, but not a broad barrier to generic entry |
| Packaging and presentation |
May protect a commercial configuration without blocking the active ingredient |
| Device or delivery system |
Limited relevance because vecuronium is administered as an injectable solution after reconstitution |
Patent numbers and expiration dates for historical Norcuron filings should be verified against the original FDA application and patent records before use in litigation, diligence, or an exclusivity opinion. Publicly available current market data do not support treating Norcuron as an actively protected branded asset.
How many patents cover Norcuron today?
No material active U.S. patent estate appears to protect Norcuron as a branded commercial franchise. The relevant distinction is between historical patent listings and patents that can block current generic vecuronium products.
A patent may appear in a historical Orange Book record yet have no current blocking value because it has expired, been disclaimed, or relates to a discontinued presentation. For current diligence, the critical conclusion is that generic vecuronium bromide products are not generally excluded by Norcuron patent rights.
What is the Orange Book status of Norcuron?
Norcuron’s Orange Book significance is primarily historical. The Orange Book identifies reference listed drugs, therapeutic equivalence information, patent listings, and exclusivity data. Generic vecuronium bromide products may rely on the reference product while competing under ANDAs.
The relevant Orange Book questions are:
- Is the historical Norcuron reference product listed?
- Is the product currently marketed?
- Are patents listed, and are they expired?
- Which generic products have therapeutic-equivalence designations?
- Has FDA determined that the reference product was withdrawn for safety or effectiveness reasons?
A historical or discontinued brand designation does not necessarily remove the active ingredient from the U.S. market. Generic vecuronium injection can remain available even when the original Norcuron brand has little or no commercial presence.
What formulation patents protect vecuronium injection?
Vecuronium bromide is generally supplied as a sterile lyophilized powder that is reconstituted before intravenous administration. The formulation is technically demanding because the product must meet injectable-drug requirements for sterility, potency, particulate matter, stability, container closure, and reconstitution performance.
Formulation-related protection is more likely to arise from:
- Lyophilization parameters
- Excipient selection
- pH control
- Stability during storage
- Container-closure systems
- Reconstitution time and dilution compatibility
- Manufacturing controls for sterile injectable production
These issues can create manufacturing complexity without creating durable market exclusivity. A process patent held by one manufacturer would not necessarily prevent another company from producing an equivalent vecuronium product through a different process.
Which companies challenge or compete with Norcuron?
Norcuron does not face a conventional branded patent challenge today. Its principal competition comes from generic vecuronium suppliers and alternative neuromuscular blockers.
Product competition
| Competitor |
Commercial role |
| Generic vecuronium bromide |
Direct active-ingredient competition |
| Rocuronium bromide |
Main same-class alternative; rapid onset and compatibility with sugammadex reversal |
| Cisatracurium besylate |
Alternative for patients in whom organ-independent metabolism is valued |
| Atracurium besylate |
Older alternative with different metabolism and side-effect considerations |
| Pancuronium bromide |
Longer-acting, older generic alternative |
| Succinylcholine |
Depolarizing blocker used particularly for rapid-sequence intubation |
Rocuronium is the most important clinical and commercial comparator. Its rapid onset and the availability of sugammadex can support substitution away from vecuronium in operating rooms with access to the reversal agent. Vecuronium can retain demand where hospitals prioritize lower acquisition cost, established protocols, or existing formulary familiarity.
How strong is the Norcuron patent estate?
The Norcuron patent estate is commercially weak because the product is mature, genericized, and clinically substitutable. Its residual competitive advantages do not arise from patent protection.
| Strength factor |
Assessment |
| Composition-of-matter protection |
None of current commercial significance |
| Formulation protection |
Limited and unlikely to block broad generic entry |
| Method-of-use protection |
Low practical value |
| Manufacturing know-how |
Moderate importance for reliable sterile supply |
| Regulatory complexity |
Moderate |
| Switching costs |
Low to moderate at the hospital protocol level |
| Brand loyalty |
Low |
| Pricing power |
Low |
| Litigation leverage |
Low |
The strongest barriers are operational rather than legal. A supplier must maintain validated sterile manufacturing, reliable API sourcing, FDA compliance, and hospital distribution. These barriers can restrict the number of dependable suppliers even when patent barriers are absent.
What patent litigation affects Norcuron?
No major current U.S. patent litigation involving Norcuron is central to the product’s market position. Vecuronium is not generally treated as an active branded litigation asset, and generic entry is not primarily constrained by Paragraph IV disputes.
Historical ANDA filings may have included Paragraph IV certifications against expired or nonblocking patents. Those certifications would not create current commercial exclusivity unless accompanied by a valid, unexpired patent and litigation outcome with continuing legal effect.
Are there Paragraph IV challenges to Norcuron?
Paragraph IV litigation is not a major current market driver for vecuronium bromide. A generic applicant can challenge listed patents by certifying that a patent is invalid, unenforceable, or will not be infringed. For a mature product such as Norcuron, the relevant patents are generally expired or commercially immaterial.
The absence of active Paragraph IV litigation does not mean that FDA-approved generic competition is absent. It means the competitive pathway is largely complete and no current patent dispute is preventing ordinary generic supply.
What are the main market dynamics for vecuronium bromide?
Vecuronium is a hospital injectable with low consumer visibility and limited direct-to-patient demand. Its market is shaped by institutional purchasing.
1. Generic price erosion
After loss of exclusivity, multiple suppliers can compete on acquisition price. Hospitals and group purchasing organizations negotiate contracts based on unit cost, shortage history, delivery reliability, and portfolio breadth.
2. Low absolute market size
Vecuronium is used in anesthesia and intensive-care settings, but it is not a high-volume outpatient medicine. Demand is measured through hospital procedure volume, operating-room activity, critical-care utilization, and inventory policies.
3. Supply concentration
Sterile injectables are vulnerable to manufacturing interruptions. A small number of qualified suppliers, plant shutdowns, raw-material constraints, or quality remediation events can cause shortages even when demand is stable.
4. Substitution by rocuronium
Rocuronium competes directly with vecuronium. Sugammadex has strengthened rocuronium’s position in some operating rooms because it provides a selective reversal option. The acquisition cost of sugammadex can offset part of that clinical advantage.
5. COVID-related volatility
During the COVID-19 pandemic, intensive-care ventilation increased demand for neuromuscular blockers and other injectable medicines. The effect was episodic rather than a durable structural expansion of Norcuron revenue.
6. Protocol and monitoring requirements
Use requires trained anesthesia or critical-care personnel, neuromuscular monitoring, ventilation support, and appropriate reversal or recovery management. These requirements constrain the market to controlled clinical settings.
What is Norcuron’s financial trajectory?
Norcuron’s standalone financial trajectory is not publicly disclosed in a reliable, recurring series. The product was historically associated with Organon, but public company reporting does not provide a transparent current Norcuron revenue line.
The most defensible financial assessment is:
| Financial phase |
Expected trajectory |
| Branded launch and early adoption |
Revenue growth supported by clinical adoption and branded pricing |
| Generic entry |
Sharp pricing pressure and share fragmentation |
| Mature generic period |
Low, stable, or declining nominal revenue |
| Shortage periods |
Temporary price and volume increases for available suppliers |
| Current market |
Low-value, contract-driven hospital product with limited brand economics |
Revenue exposure for any individual supplier depends on product availability, contract wins, manufacturing capacity, and shortage conditions. A supplier can experience temporary revenue expansion without gaining durable market power.
Financial metrics that matter
Public-market analysis should focus on:
- Hospital contract retention
- Average selling price per vial
- Annual unit volume
- Back-order and shortage frequency
- Cost of goods and sterile manufacturing yield
- API availability
- FDA warning letters or remediation activity
- Share of revenue from vecuronium relative to the supplier’s full injectable portfolio
- Gross margin during shortage periods
- Competitive tender outcomes
Norcuron is unlikely to have material standalone revenue exposure for a diversified pharmaceutical company. Its financial significance is greater as part of a broader hospital-injectable portfolio than as an independent brand.
What generic launch scenarios exist for vecuronium?
Scenario 1: Stable multi-supplier market
Several approved suppliers maintain inventory, price competition remains intense, and vecuronium retains a small but stable role in anesthesia formularies. This is the base case for a mature injectable.
Scenario 2: Supplier exit
One or more manufacturers leave the market because of low margins, compliance costs, or manufacturing problems. Remaining suppliers gain volume and may obtain temporary pricing leverage.
Scenario 3: Shortage-driven substitution
Hospitals substitute rocuronium, cisatracurium, or other neuromuscular blockers when vecuronium is unavailable. Substitution can persist if clinicians revise protocols or procurement systems.
Scenario 4: Demand rebound
An increase in elective surgery or critical-care utilization raises unit demand. The effect would likely be volume-driven and limited by generic pricing.
Does Norcuron have biosimilar risk?
No. Norcuron contains a chemically synthesized small-molecule active ingredient, vecuronium bromide. Biosimilar regulation applies to biological products, not conventional small-molecule injectable drugs.
The relevant competitive risks are generic ANDA entry, therapeutic substitution, hospital contracting, and supply disruption. Calling vecuronium competitors “biosimilars” would be legally and technically incorrect.
What manufacturing and intellectual-property barriers remain?
The key barriers are production and compliance rather than patents.
Manufacturing barriers
- Sterile injectable production
- Lyophilization and reconstitution performance
- Validated aseptic processing
- Container-closure integrity
- Stability testing
- Batch release controls
- Reliable vecuronium bromide API supply
- FDA inspection compliance
Geographic coverage
The market is jurisdiction-specific. U.S. ANDA approval does not authorize sales in Europe, Japan, Canada, or emerging markets. Each jurisdiction applies its own rules for generic approval, labeling, pharmacopoeial compliance, serialization, and pharmacovigilance.
Manufacturers with multinational sterile-injectable networks may have an advantage in supply continuity, but geographic approval does not create U.S. patent protection.
How does Norcuron compare with rocuronium?
| Factor |
Vecuronium / Norcuron |
Rocuronium |
| Market status |
Mature generic |
Mature generic with strong clinical use |
| Onset |
Intermediate |
Faster |
| Reversal |
Neostigmine; sugammadex can reverse |
Neostigmine or sugammadex |
| Patent leverage |
None of current significance |
Core exclusivity expired; formulation and product competition remain |
| Price profile |
Usually lower acquisition cost |
May carry higher drug cost, with economic offset from clinical workflow |
| Main advantage |
Established, lower-cost option |
Faster onset and selective sugammadex reversal |
| Main commercial risk |
Substitution and supply volatility |
Competition from other generics and reversal-agent cost |
Rocuronium has a stronger clinical-commercial position in rapid-sequence and operating-room settings, while vecuronium remains relevant as a lower-cost established generic.
Key Takeaways
- Norcuron is the historical brand for vecuronium bromide, an intravenous nondepolarizing neuromuscular blocker.
- The product has lost meaningful patent and regulatory exclusivity.
- Current competition is generic and hospital-contract driven.
- No active Norcuron patent estate appears to create a material barrier to generic vecuronium entry.
- Paragraph IV litigation is not a major current market driver.
- Vecuronium has no biosimilar exposure because it is a small-molecule drug.
- Rocuronium is the main clinical and commercial substitute, particularly where sugammadex is available.
- Financial performance is not publicly reported as a standalone Norcuron revenue stream.
- The principal investment risks are sterile-manufacturing disruption, supplier concentration, shortages, pricing pressure, and formulary substitution.
- Norcuron’s value is greater as part of a diversified hospital-injectable portfolio than as an independent branded asset.
FAQs
Is Norcuron still sold in the United States?
The original Norcuron brand has limited commercial significance in the United States. Vecuronium bromide remains available through generic injectable products subject to supplier and shortage conditions.
Is vecuronium bromide an FDA-approved generic?
Yes. Generic vecuronium bromide injection products can be approved through the FDA ANDA pathway, subject to bioequivalence, manufacturing, sterility, labeling, and quality requirements.
Can a generic company launch vecuronium without a Paragraph IV settlement?
Yes. For a mature product with no relevant unexpired blocking patents, a generic applicant may proceed without relying on a patent settlement. The applicable launch date depends on FDA approval and any remaining enforceable patent or regulatory restriction.
Is Norcuron used for rapid-sequence intubation?
Vecuronium can be used for neuromuscular blockade, but rocuronium or succinylcholine is often preferred when rapid onset is the primary requirement. Clinical selection depends on patient factors, institutional protocols, and reversal strategy.
Does Norcuron generate material revenue for Organon?
A current standalone Norcuron revenue figure is not publicly reported. Given the product’s mature generic status, any remaining revenue exposure would be expected to be small relative to a diversified pharmaceutical portfolio.
References
-
U.S. Food and Drug Administration. (n.d.). Norcuron (vecuronium bromide) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug product list and abbreviated new drug applications. FDA.
-
Organon. (n.d.). Norcuron product information. Organon.
-
U.S. Food and Drug Administration. (2020). Drug shortages and supply-chain information for injectable medicines. FDA.
-
U.S. Food and Drug Administration. (n.d.). Generic drugs: Questions and answers. FDA.
